Van Rhenen et al. showed that the CD34+CD38− population in AML and high-risk MDS samples at diagnosis is resistant to chemotherapy, and detection of this population using FACS assay can be used for monitoring the disease and characterization of chemotherapy-resistant neoplastic cells [119]. This evidence concerns the gene CD34 and myelodysplastic syndrome.